Home Market Extra: Why share volume of tiny biotech Celator is surpassing that of Apple
 

Keywords :   


Market Extra: Why share volume of tiny biotech Celator is surpassing that of Apple

2016-03-15 21:31:47| Biotech - Topix.net

Investors on Tuesday are more interested in what may be the newest way in more than 40 years to better treat a type of deadly blood cancer than they are the next iteration of Apple Inc.'s iPhone. shot into the stratosphere late Monday after the company reported a late-stage, Phase 3 study showed its drug Vyxeos significantly improved the average survival of patients with acute myeloid leukemia , compared with the current standard-of-care chemotherapy.

Tags: of share market volume

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news

»
27.11
27.11PSA10 SSP
27.11
27.11
27.11
27.115
27.11BTR 20()competition
27.11DVD
More »